Corporate presentation highlights cash position and pipeline updates
Compugen highlighted a cash balance of $125.3 million as of June 30, 2026, with expected runway into 2029.
The COM701 maintenance study in relapsed platinum-sensitive ovarian cancer targets an interim analysis in Q1 2027.
AstraZeneca’s rilvegostomig program entered Phase 3, with Compugen eligible for up to $195 million in milestones and tiered royalties up to the mid-single digit range.
The Gilead-licensed GS-0321 anti-IL-18BP program advanced in Phase 1; the deal value is up to $848 million with single- to low double-digit royalties.
The pipeline remains focused on novel immuno-oncology antibodies discovered via the Unigen AI/ML target discovery platform.
CGEN•
